Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05189457
Title First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute

prostate cancer


Docetaxel + Triptorelin

Degarelix + Enzalutamide

Enzalutamide + Triptorelin

Docetaxel + Leuprolide

Docetaxel + Relugolix

Docetaxel + Goserelin

Degarelix + Docetaxel

Enzalutamide + Relugolix

Enzalutamide + Goserelin

Abiraterone + Leuprolide

Docetaxel + Tislelizumab

Enzalutamide + Leuprolide

Abiraterone + Goserelin

Abiraterone + Triptorelin

Abiraterone + Degarelix

Abiraterone + Relugolix

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.